Variations of Particle Size Distribution, Black Carbon, and Brown Carbon during a Severe Winter Pollution Event over Xi'an, China

Real-time particulate matter (PM) size distributions, 4-hour time resolution, PM2.5, carbonaceous materials, and their optical properties were measured during a severe pollution event in Xi'an, China High PM2.5 /PM10 ratios were observed on both pollution (0.83) and non-pollution (0.73) days, emphasizing the abundance of fine particles during sampling days. The particle number (PN) first peaked with a wide size range (30-100 nm) before morning rush hours (approximately 01:00-05:00) on pollution and non-pollution days, demonstrating that PN was governed by the accumulation of freshly emitted diesel particles and characterized by distinct aerosol condensation growth. By contrast, the second peak time and size range differed between pollution and non-pollution days because of different formation mechanisms The light-absorbing coefficients of both black carbon (BC, b(abs-880nm,BC)) and brown carbon (BrC, b(abs-370nm, BrC)) were high on pollution days and decreased to approximately half of those values on non-pollution days, indicating that the degree of light absorption is reduced by rain. The diurnal variation in b(abs-880nm, BC) pollution peaked with traffic on January 1 and 2. By contrast, it remained in relatively stable and high ranges (120-160 Mm(-1)) in the second period (January 3-5) without traffic peaks, illustrating that the dominant sources changed even during the same pollution period. High values of both b(abs-370nm, BrC) and b(abs-880nm,) (BC )coincided in the afternoon and evening due to emissions from primary sources, and abundant aqueous secondary organic carbon, respectively. A highly variable mass absorption coefficient of BrC also indicated the variety of fuel combustion sources of primary BrC in Xi'an

Improved measurement of the reactor antineutrino flux and spectrum at Daya Bay

published_or_final_versio

Search for a Light Sterile Neutrino at Daya Bay

published_or_final_versio

The muon system of the Daya Bay Reactor antineutrino experiment

postprin

Determination of the number of J/ψ events with J/ψ → inclusive decays

postprin

Higher-order multipole amplitude measurement in ψ ′→γχ c2

Using 106×106 ψ ′ events collected with the BESIII detector at the BEPCII storage ring, the higher-order multipole amplitudes in the radiative transition ψ ′→γχ c2→γπ +π -/γK +K - are measured. A fit to the χ c2 production and decay angular distributions yields M2=0.046±0. 010±0.013 and E3=0.015±0.008±0.018, where the first errors are statistical and the second systematic. Here M2 denotes the normalized magnetic quadrupole amplitude and E3 the normalized electric octupole amplitude. This measurement shows evidence for the existence of the M2 signal with 4.4σ statistical significance and is consistent with the charm quark having no anomalous magnetic moment. © 2011 American Physical Society.published_or_final_versio

Measurement of electron antineutrino oscillation based on 1230 days of operation of the Daya Bay experiment

published_or_final_versio

Improved Search for a Light Sterile Neutrino with the Full Configuration of the Daya Bay Experiment

published_or_final_versio

Independent measure of the neutrino mixing angle θ13 via neutron capture on hydrogen at Daya Bay

published_or_final_versio

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.